Lung Cancer Treatment in Germany: Biomarker Testing Before Immunotherapy or Targeted Therapy

Last updated: May 30, 2026

This article is educational and is not a substitute for diagnosis or treatment from a licensed oncologist. Cancer care changes quickly, and international treatment decisions should be based on your actual pathology, imaging, biomarkers, health status, and treatment goals.

Quick Answer

For advanced non-small cell lung cancer, biomarker testing can change the entire treatment plan. Before traveling to Germany for immunotherapy, chemotherapy, or targeted therapy, patients should confirm that pathology, staging, PD-L1, and actionable mutation testing are complete or will be repeated.

Related guides in this oncology cluster: Stage 4 Lung Cancer Treatment Abroad, Immunotherapy Abroad, Cancer Treatment in Germany for Foreign Patients.

Who This Guide Is For

Patients with non-small cell lung cancer, especially advanced or metastatic disease, who are considering German oncology care.

The practical search intent behind “lung cancer treatment Germany biomarker testing” is usually not just curiosity. Patients want to know whether the option is medically appropriate, how to avoid paying for the wrong care, what records are needed, and how to compare the recommendation with local treatment.

Key Takeaways

• Biomarker testing is central in many advanced lung cancer cases because targeted therapies may work better than nonspecific chemotherapy for certain mutations.
• Starting immunotherapy before an EGFR or ALK result can complicate later treatment in some patients, so sequence matters.
• A German second opinion should review tissue adequacy, liquid biopsy, PD-L1, brain imaging, and metastatic burden.
• Clinical trials may be relevant when standard targeted options are exhausted or no actionable mutation is found.

Decision Map

How to Evaluate This Option

Lung cancer is one of the strongest SEO topics for international oncology because the treatment plan can change dramatically after molecular testing. A patient with EGFR-mutated disease, ALK rearrangement, high PD-L1 without driver mutation, or no actionable markers may receive very different first-line therapy.

Germany may be valuable when local testing is incomplete, the biopsy tissue is limited, disease is progressing after targeted therapy, or a trial might match resistance mutations. The second opinion should ask whether additional tissue biopsy or liquid biopsy is needed.

For stage 4 disease, the goal is often disease control and quality of life rather than surgery. However, some oligometastatic or locally advanced cases need a multidisciplinary decision about chemotherapy, immunotherapy, radiation, and local consolidation.

Patients should avoid choosing a clinic based only on a promise of immunotherapy. Immunotherapy is not one treatment for all lung cancer. Some molecular subtypes need targeted therapy first, and autoimmune disease or organ transplant history can change risk.

Cost and Timeline Questions

• Ask whether next-generation sequencing, PD-L1, liquid biopsy, brain MRI, PET/CT, and repeat biopsy are included.
• Drug costs can dominate the budget for targeted therapy or immunotherapy.
• If comparing countries, see stage 4 lung cancer treatment abroad.
• Use immunotherapy abroad before paying for a generic immunotherapy package.

Medical Records Checklist

• Pathology report, immunohistochemistry report, and information on where the tissue block or slides are stored.
• Imaging reports and DICOM files for CT, MRI, PET/CT, bone scan, mammography, ultrasound, or nuclear medicine studies.
• Operation reports, radiation summaries, discharge summaries, and any complications that changed the treatment plan.
• Systemic therapy history: drug names, dates, doses, dose reductions, response, progression dates, and serious side effects.
• Biomarker, molecular, genomic, cytogenetic, and germline genetic reports, even if a later hospital plans to repeat testing.

Questions to Ask the Oncologist

1. What diagnosis, stage, grade, and molecular subtype are you using to make the recommendation?
2. What parts of the plan are standard of care, and what parts are optional, experimental, or available only in a trial?
3. What result would change the plan: new pathology, a biomarker result, a new scan, or a multidisciplinary tumor board review?
4. How quickly does treatment need to start, and is travel medically safe during that waiting period?
5. What costs are included in the written estimate, and what costs could be billed separately?

Red Flags Before You Pay

• A clinic promises a cure before reviewing pathology, staging scans, and prior treatment history.
• The provider asks for full payment before giving a named physician, treatment plan, and written cost estimate.
• The recommendation ignores biomarker testing for a cancer where biomarkers commonly guide treatment.
• The clinic discourages you from discussing the plan with your current oncologist.
• A paid treatment is described as a clinical trial but is not listed in a recognized registry or ethics-approved protocol.

Internal Reading Path

• Stage 4 Lung Cancer Treatment Abroad
• Immunotherapy Abroad
• Cancer Treatment in Germany for Foreign Patients
• Clinical Trials for Cancer in the USA

Sources

• NCI: Non-Small Cell Lung Cancer Treatment
• NCI: Biomarker Testing for Cancer Treatment
• NCI: Targeted Therapy to Treat Cancer
• NCI: Immunotherapy to Treat Cancer
• NCI: Find NCI-Supported Clinical Trials